Trial Profile
A Phase II Study of Ibrutinib Followed by Ibrutinib in Combination With Nivolumab in Advanced Non-Small Cell Lung Cancer
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 15 Feb 2017
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary) ; Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 10 Feb 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 04 Nov 2016 New trial record